Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major ...

AbbVie is a popular stock with dividend investors for its high starting yield and continuous dividend increases. AbbVie is a ...

Paul Stoffels left his perch as J&J’s chief scientific officer in 2022 to replace Galapagos’ founding CEO Onno van de Stolpe, ...

We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to ...

Analysts on Wall Street project that AbbVie (ABBV) will announce quarterly earnings of $2.40 per share in its forthcoming report, representing an increase of 3.9% year over year. Revenues are ...

BofA lowered the firm’s price target on AbbVie (ABBV) to $200 from $223 and keeps a Neutral rating on the shares. The firm updated estimates ...

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an ...

Cantor Fitzgerald initiated or transferred coverage on 10 large-cap U.S. biopharma stocks in a note Tuesday, highlighting a selective approach that favors dominant franchises with strong growth ...

Because of its two popular medications, Skyrizi and Rinvoq, analysts are upbeat about AbbVie Inc. (NYSE:ABBV)’s growth. As one of the best pharmaceutical stocks, the yearly sales of these ...

Merck MRK and AbbVie ABBV are leading pharmaceutical companies with strong portfolios in oncology and immunology. While ...

Additionally, AbbVie developed new immunology drugs in Skyrizi and Rinvoq.These moves are paying off. Skyrizi and Rinvoq were two of AbbVie's top three sellers in 2024. AbbVie's revenue dropped ...